Media

Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019), Deepinder K Dhaliwal, Viktor Chirikov, Jordana Schmier, Sanika Rege, Schalon Newton Dovepress (2022)

Fine-sampled Photographic Quantitation of Dermal Wound Healing Senescence in Aged BALB/cByJ Mice and Therapeutic Intervention with FGF-1, Mellers, A., Tenorio, C.A., Lacatusu, D., Powell, B., Patel, B., Harper, K.M. and Blaber, M. Advances in Wound Care 7, 409-418 (2018)

Trefoil Therapeutics Elects Benjamin F. McGraw, III, to its Board of Directors

Trefoil Therapeutics Raises $5.2 Million Series 1 Financing

Trefoil Therapeutics Enters Into Collaborative Research and Development Agreement with National Institutes of Health’s National Center for Advancing Translational Sciences

Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “2nd Generation” Therapeutic Application, Xia, X., Kumru, O.S., Blaber, S.I., Middaugh, C.R., Li, L., Ornitz, D.M., Sutherland, M.A., Tenorio, C. and Blaber, M., J. Pharm. Sci. 105, 1444-53 (2016)

Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “2nd Generation” Therapeutic Application, Xia, X., Kumru, O.S., Blaber, S.I., Middaugh, C.R., Li, L., Ornitz, D.M., Sutherland, M.A., Tenorio, C. and Blaber, M., J. Pharm. Sci. 105, 1444-53 (2016)

Trefoil Therapeutics and E&B Technologies Awarded NIH R21 Grant for Evaluation of Engineered FGF-1 Derivatives as Therapy for Ocular Surface Injury

Mutation Choice to Eliminate Buried Free Cysteines in Protein Therapeutics, Xia, X., Longo, L.M. and Blaber, M. J. Pharm. Sci. 104, 566–576 (2015) PMID: 25312595

Trefoil Therapeutics To Present Data on Novel Class of Engineered FGF-1 Compounds at ARVO 2015 Meeting